Page 2 - Natco Pharma Ltd

Natco in legal fight with FMC to produce CTPR based insecticide in India

Natco is also awaiting regulatory approval for a product based on CTPR, which is a broad spectrum insecticide used in several crops

Natco Pharma to expand API facility in TN with Rs 100 cr investment

At a time when the pharmaceutical industry in the State are complaining lack of government support in the State, Hyderabad-based Natco Pharma is planning to expand its Active Pharmaceutical Ingredient (API) and intermediates manufacturing facility and R&D in Tamil Nadu. The company is looking at investing in its existing facility, in Thiruvallur District.The company would be investing around Rs 100 crore in addition to the existing investmenbt of Rs 86.82 crore in the facility to manufacture 16 campaign products at a time, out of 42 API products and R&D activity, with a production capacity of 66.32 tonnes per annum from existing production capacity of 46.267 tonnes per annum. The proposed expansion is in a total land of 10.57 hectre in possession of the company.According to an environmental impact assessment report submitted in connection with the expansion plan, the expansion is in order to meet the growing market demand for pharmceutical products in the country.The proposed .

Natco Pharma gets environmental nod for API plant expansion in Telangana

Project is expected to employ 1,200 persons directly and 300 persons indirectly after the expansion

Natco Pharma gets green nod for Rs 480-cr expansion project in Telangana

Clearance is subject to compliance of certain conditions; Project expected to create 1,500 jobs

Natco Pharma launches generic blood cancer drug in India for Rs 5,000

Shares of Natco Pharma were trading 1.52 per cent up at Rs 909 on BSE

Natco Pharma Q2 net profit up 127% at Rs 66 crore

Revenue and profit growth was driven by the surge in formulation business, according to Natco

Natco Pharma's net profit up 70% in June quarter

Hyderabad-based Natco Pharma Limited has reported a 69.7 per cent jump in its consolidated net profit at Rs 47.6 crore for the quarter ended June, on the back of an increase in revenue from formulations. The company's net profit was Rs 28.07 crore in the corresponding period last year.

Natco Pharma Q4 net profit up 10.65% at Rs 60.24 crore

The total income from operations in this 4th quarter doubled at Rs 406.97 cr from Rs 200.8 cr in the year ago period